Nab-Paclitaxel Improves Progression-free Survival in Metastatic Melanoma

Share this content:
Nab-paclitaxel significantly improved progression-free survival and disease control rate in patients with metastatic melanoma.
Nab-paclitaxel significantly improved progression-free survival and disease control rate in patients with metastatic melanoma.

Nab-paclitaxel significantly improved progression-free survival and disease control rate compared with dacarbazine, with a manageable safety profile, in patients with metastatic melanoma, a new study published online ahead of print in the journal Annals of Oncology has shown.1

For the study, researchers sought to evaluate the efficacy and safety of nab-paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

Researchers enrolled 529 chemotherapy-naïve patients with stage 4 melanoma and randomly assigned them to receive nab-paclitaxel 150 mg/m2 intravenously on days 1, 8, and 15, every 28 days or dacarbazine 1,000 mg/m2 intravenously every 21 days.

Most of patients enrolled were male, had an ECOG performance status of 0, and had M1c stage disease.

Results showed that median progression-free survival was 4.8 months with nab-paclitaxel compared with 2.5 months with dacarbazine (HR = 0.792; 95.1% CI: 0.631-0.992; P=0.044). Disease control rate was 39% and 27%, respectively (P=0.004).

RELATED: We Can Treat Hodgkin's Lymphoma Like Melanoma?

However, researchers observed no statistically significant difference in median overall survival (12.6 months vs 10.5 months; HR=0.897; 95.1% CI: 0.738-1.089; P=0.271) or overall response rate (15% vs 11%; P=0.239).

In regard to safety, the most frequent grade 3 or higher nab-paclitaxel-related adverse events were neuropathy and neutropenia.

Reference

  1. Hersh EM, Del Vecchio M, Brown MP, et al. A randomized, controlled phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma [published online ahead of print September 26, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv324.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs